Pross MD launches Bijuva (estradiol and progesterone capsules, 1mg/100mg) in the U.S. market

menopause is a transitional period in a woman's normal life, usually at the beginning of an average of 51 yearsAccording to the U.SCensus Bureau, about 43 million women in the U.Sare in menopause (45-64 years old), and more than a third of women's life during menopause is associated with menopausal-related conditionsrecently,(http:// of Theof Therapeutics MDannouncedthe launch of Bijuva (estradiol and progesterone capsules, 1mg/100mg) in the U.SmarketAbout Bijuva
Bijuva is a fixed-dose
combination of 1 mg estradiol and 100 mg progesterone, a fixed-dose combination of 1 mg estradiol and 100 mg progesterone http://
, acapsule that was approved by the U.SFDA (http:// at the end of October 2018 and is the first and only biologically identical (bio-identical) hormone combination therapy that binds estradiol and progesterone to a single oral capsule Bijuva Indications: One pill daily orally as a hormone replacement therapy for moderate to severe vascular destrophy symptoms (often referred to as "hot or hot flashes") caused by menopause in women 　　Bijuva will provide a proven balance that the same estradiol, which reduces moderate to severe hot flashes, and the same progesterone in organisms that combine to reduce endometrial risk It should be noted that "biologically identical" means estradiol and progesterone, which are molecularly identical to the hormones that circulate naturally in women There is no evidence that biologically identical hormones are safer or more effective than synthetic (http:// hormones